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Introduction
As demonstrated by the 2009 H1N1 pandemic, novel influenza 
viruses can spread rapidly when limited immunity exists within 
the worldwide population. Due to the variability of influenza 
virus strains from year to year, a new vaccine based on the circu-
lating strains (and their HA and NA proteins) is made available 
as often as every year, if necessary. These reformulated versions 
of the seasonal influenza virus are not always protective, due to a 
range of factors including genetic drift. There is an urgent need 
to develop novel influenza vaccines that will provide more uni-
versal protection against influenza infection in a shorter time 
frame than is currently feasible.
Because of the unique epidemiology of 2009 H1N1 influenza, 
we hypothesized that T-cell responses to cross-reactive epitopes 
might have contributed to diminished reports of influenza-like 
illnesses and confirmed infection among older adults in the 
absence of cross-reactive humoral immunity. There is consider-
able support for this hypothesis in published studies involving 
exposure or vaccination and heterotypic challenge in animal 
The emergence of the pandemic H1N1 strain of influenza in 2009 was associated with a unique w-shaped age-related 
susceptibility curve, with higher incidence of morbidity and mortality among young persons and lower incidence among 
older persons, also observed during the 1918 influenza pandemic. Pre-existing H1N1 antibodies were not cross-reactive 
with the prior seasonal vaccine, forcing influenza experts to scramble to develop a new vaccine specific for the pandemic 
virus. We hypothesized that response to T-cell epitopes that are cross-conserved between pandemic H1N1 and the 
2008 seasonal influenza vaccine strains might have contributed to partial protection from clinical illness among older 
adults, despite the lack of cross-reactive humoral immunity. Using immunoinformatics tools, we previously identified 
hemagglutinin and neuraminidase epitopes that were highly conserved between seasonal and pandemic H1N1. Here, 
we validated predicted cD4+ T-cell epitopes for their ability to bind HLa and to stimulate interferon-γ production in 
peripheral blood mononuclear cells from a cohort of donors presenting with influenza-like illness during the 2009 
pandemic and a separate cohort immunized with trivalent influenza vaccine in 2011. a limited-epitope heterologous 
DNa-prime/peptide-boost vaccine composed of these sequences stimulated immune responses and lowered lung 
viral loads in HLa DR3 transgenic mice challenged with pandemic 2009 H1N1 influenza. cross-priming with conserved 
influenza T-cell epitopes such as these may be critically important to T cell-mediated protection against pandemic H1N1 
in the absence of cross-protective antibodies.
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models.1-4 One explanation for the unusual age distribution 
is that, similar to the 1918 epidemic and again as occurred in 
1977,5,6 older individuals might have established a cross-reactive 
cell-mediated immune response to novel H1N1 due to having 
been vaccinated or exposed to circulating influenza H1N1.7 
While cross-reactive T-cell responses (in the absence of a cross-
reactive humoral immune response) may not have provided com-
plete protection against infection, it is possible that the severity 
of the illness was reduced, leading to a lower hospitalization rate 
and lower reports of H1N1 in this age group, as was observed in 
a case-control study from Mexico.8
We previously performed an immunoinformatics analysis 
to define cross-conserved HA and NA CD4+ T-cell epitopes 
between the emerging pandemic strain and the prior seasonal 
influenza vaccine strains, using the A/California/04/2009 
sequence as a departure point. The analysis was performed in 
March 2009, immediately following publication of the virus 
sequence.9,10 Here we present results from in vitro studies con-
firming these predictions. The cross-conserved epitopes bound to 
multiple HLA and were antigenic in recall assays using peripheral 
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despite immunoinformatic predictions it would bind all assayed 
alleles except DRB1*0701. In our experience testing thousands 
of peptides predicted to bind HLA, this is a singularly unusual 
finding. It may be explained by self-association, which would 
interfere with HLA interactions no matter what allele is assayed. 
Given this highly unusual result, we exclude the peptide from 
the following summary of binding results for the group of 
peptides.
Of the 54 peptide-HLA binding interactions assayed, 18.5% 
were very high affinity, 22.2% high affinity, 22.2% moder-
ate affinity, 9.3% low affinity, 1.9% very low affinity, and no 
measurable affinity was observed for 25.9% (Fig. 1). The con-
cordance of computational predictions and binding assay results 
was evaluated with classification of peptide-HLA binding pairs 
as either true positive, false positive, true negative, or false nega-
tive. A non-binder was defined as a confirmed true negative pre-
diction if the peptide had an EpiMatrix Z-score that was lower 
than the defined cut-off (1.64) for its associated HLA allele. 
Positive predictions were defined as epitopes scoring ≥1.64 on the 
EpiMatrix Z-scale and binding HLA at any affinity. Overall, the 
concordance with predictions (both positive and negative) was 
76%. With respect to each allele assayed, the values are 78% for 
DRB1*0101, 89% for DRB1*0301, 67% for DRB1*0401, 78% 
for DRB1*0701, 89% for DRB1*1101, and 56% for DRB1*1501. 
blood mononuclear cells (PBMCs) from a patient presenting with 
influenza-like illness during the recent pandemic and in a cohort 
of 2011 trivalent influenza virus (TIV) vaccines. Vaccination 
with cross-conserved influenza epitopes stimulated de novo 
T-cell responses that lower viral burden in HLA transgenic mice, 
despite an absence of vaccine-induced antibodies. These stud-
ies appear to support the hypothesis that cross-protective T-cell 
responses might have played a role in reducing influenza morbid-
ity and mortality in humans.
Results
HLA binding properties of cross-conserved H1N1 influenza 
epitopes. In a previous study, we identified peptide sequences 
from 2008–2009 influenza A seasonal vaccine HA and NA 
antigens that are cross-conserved with the corresponding anti-
gens from 2009 pandemic H1N1 and potentially immunogenic, 
using the EpiMatrix T cell epitope mapping algorithm.9 These 
sequences were assayed in vitro for their capacity to bind multiple 
HLA types, including DRB1*0101, DRB1*0301, DRB1*0401, 
DRB1*0701, DRB1*1101, and DRB1*1501. Ninety percent of 
the peptides bound as predicted to at least 3 HLA alleles, 70% 
to at least 4 HLA alleles, 60% to at least 5, and 10% to all 
6. Surprisingly, peptide HA_112–129 did not bind any HLA 
Figure 1. HLa DR binding affinities for immunoinformatic-predicted H1N1 influenza cross-conserved epitopes. Peptide identifiers and sequences 
are noted in the first and second columns, respectively. Ic50 values in μM units were calculated from curves fitted to dose-dependence competition 
binding data for each peptide-HLa DR allele pair. Peptide binding affinity is shown according to the following classification: Ic50 < 1 μM (black), 1 μM < 
Ic50 < 10 μM (dark gray), 10 μM < Ic50 < 50 μM (gray), 50 μM < Ic50 < 100 μM (light gray), Ic50 > 100 μM (lightest gray). Ic50 values too high to accurately 
measure under binding conditions tested are considered non-binders (NB; shown in white cells).
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Epitope-specific IFNγ responses: 2011 TIV-immunized 
subjects. To better determine the antigenic potential of cross-
conserved H1N1 peptides, we expanded low frequency influ-
enza-specific T cells over a nine-day period using PBMC samples 
collected before and three weeks following 2011 TIV vaccination 
of 16 young and elderly adult subjects. Cells were expanded by 
stimulation with a pool of HA and NA cross-conserved peptides 
and then re-stimulated with pooled or individual peptides for 
These HLA-binding and epitope prediction results are consistent 
with previously published studies using the same algorithms and 
assay conditions.11
Epitope-specific IFNγ responses: Acute ILI subjects. Ex vivo 
IFNγ ELISpot assays were performed using PBMCs from six 
patients ages 18 to 65 y old, who were admitted to the Rhode Island 
Hospital with influenza-like illness between November 2009 and 
February 2010 (Table 1). RT-PCR detection of influenza in nasal 
washes confirmed pandemic H1N1 infection in one subject and 
no influenza infection in the others. ELISpot responses were con-
sidered positive when (1) the number of IFNγ spot-forming cells 
exceeded 50 per million PBMCs cultured, (2) spot counts were 
at least twice background, and (3) spot counts were statistically 
different from “no stimulus” measurements (P < 0.05). In the one 
pandemic H1N1 case, significant influenza-specific IFNγ recall 
responses were observed when PBMCs were stimulated ex vivo 
with a pool of epitope peptides and with individual peptides in an 
ELISpot assay (Fig. 2). No peptide-specific ex vivo interferon-γ 
(IFNγ) responses were detected in PBMC samples taken from 
the five other subjects (data not shown). Although three of these 
subjects received the 2008–2009 TIV vaccine, the absence of an 
ex vivo response was not unexpected as we previously found that 
vaccine-specific T cells are found at low frequency and a period of 
expansion in culture is required to detect them.11
Figure 2. ex vivo human IFNγ responses elicited by cross-conserved epitopes in H1N1 influenza infection. cross-conserved epitopes were assayed for 
T cell reactivity by IFNγ eLIspot assay, using PBMcs isolated from patients that presented with influenza-like illness at Rhode Island Hospital. Data from 
the only H1N1 influenza-positive subject are presented. eLIspot responses were considered positive if three criteria were met: (1) spot-forming cells 
(sFc) per million PBMcs were at least 50 over background; (2) sFc per million PBMcs were at least 2-fold over background; and (3) antigen-stimulated 
sFc numbers were statistically different (student’s t-test; *p < 0.05, **p < 0.01) from non-stimulated counts. Data are the mean sFc over background 
per million PBMcs that secrete IFNγ in response to individual and pooled influenza Ha and Na cross-conserved epitopes are presented. The 50 sFc 
over background per million PBMcs cutoff is denoted by the dotted line.
Table 1. characteristics of cohort presenting with ILI during 2009 H1N1 
pandemic
Patient 
ID
Seasonal 
vaccine 
2009–2010
Seasonal 
vaccine 
2008–2009
Viral infection
Ex vivo 
T-Cell 
response
eP1 Yes Yes None No
eP2 No No adenovirus No
eP3 No No None No
1_0103 No Yes None No
1_0104 No Yes None No
1_0107 No No H1N1 Yes
column headers: human subject ID code; vaccination status in 2008–
2009 and 2009–2010 influenza seasons; viral diagnostic assay result; ex 
vivo IFNγ eLIspot response.
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cohort with broader HLA coverage, comparing multiple cyto-
kine responses. Notably, while both these peptides stimulated no 
IFNγ response among vaccinated subjects even after a period of 
T-cell expansion, robust ex vivo responses were observed in the 
one subject infected during the 2009 pandemic (Fig. 2). While 
trends, let alone conclusions, cannot be drawn from a single sub-
ject, we can speculate that live virus infection stimulates different 
T cell specificities than TIV vaccination.
Multi-epitope DNA vaccine construction. Following in vitro 
antigenicity testing, we set out to evaluate the in vivo immu-
nogenicity of cross-conserved H1N1 influenza epitopes using a 
heterologous DNA-prime/peptide-boost vaccination strategy. To 
design the DNA vaccine, epitope sequences were initially joined 
end to end in a random order. To avoid production of neo-epitopes 
at epitope junctions, the VaccineCAD algorithm was used to re-
arrange epitopes in an order that diminishes potential junctional 
immunogenicity. This algorithm iteratively rearranges strings of 
epitopes while assessing junctional immunogenicity, prioritizing 
those sequences that contain the fewest junctional epitopes. The 
default order contained significant predicted immunogenicity at 
a single junction (EpiMatrix score ~10). Re-ordering of epitopes 
by VaccineCAD yielded a sequence with minimized junctional 
immunogenicity (EpiMatrix scores < −3), well below the thresh-
old for potential immunogenicity.
Immunogenicity and efficacy of cross-conserved H1N1 
influenza epitopes. We evaluated the cross-conserved H1N1 
influenza epitopes for immunogenicity and efficacy in HLA 
measurement of IFNγ production by ELISpot assay. All subjects 
responded to the pool of cross-conserved peptides post-immuni-
zation by the criteria for a positive ELISpot response described 
above, apart from two subjects, one of which nearly met all 
three criteria (Fig. 3; Table S1). Two additional subjects did not 
respond prior to immunization but significant responses were 
observed in the group overall, suggesting that T-cell precursors 
for this set of epitopes do exist. The average spot forming cell 
count following T-cell expansion did not significantly increase 
post-immunization.
In individual peptide stimulations, eight out of ten (80%) epi-
topes stimulated IFNγ production greater than 50 spot forming 
cells per million PBMCs prior to immunization and vaccination 
boosted these epitope-specific responses. Differences between 
pre- and post-immunization IFNγ production were not signifi-
cant by the Wilcoxon matched-pairs signed rank test, except for 
HA_456–480 (P < 0.05). While we expected to observe signifi-
cant differences between these time points, it is very likely that 
they were lost in the course of in vitro expansion and that stimula-
tion at a lower peptide concentration would preserve differences.
Two peptides (HA_38–61 and HA_112–129) stimulated no 
significant responses in any subjects. The small cohort size of 
the study with limited HLA diversity may explain this result. 
Alternatively, these sequences may stimulate type 1 helper T cell 
cytokines other than IFNγ, such as interleukin-2 and tumor 
necrosis α. Thus, positive responses may be observed in a larger 
Figure 3. antigen-specific human IFNγ responses elicited by cross-conserved epitopes before and after 2010–2011 TIV vaccination. cross-conserved 
epitopes were assayed for T cell reactivity by cultured IFNγ eLIspot assay using PBMcs isolated from normal human donors before and three weeks 
after TIV vaccination (n = 16). assays were performed following a nine-day T cell expansion after stimulation with cross-conserved influenza epitopes. 
The numbers of sFc over background per million PBMcs that secrete IFNγ in response to individual and pooled influenza Ha and Na cross-conserved 
epitopes are presented. Individual subject average responses are represented by dots and the average response across subjects by white bars. The 50 
sFc over background per million PBMcs cutoff is denoted by the dotted line.
2064 Human Vaccines & Immunotherapeutics Volume 9 Issue 10
measured by plaque assay differed significantly between the two 
groups four days post-infection (Student t-test, P < 0.01). Lung 
viral titers were 70% lower in immunized mice four days follow-
ing infection; no significant difference was observed two days 
prior (Fig. 5). Notably, as vaccine-induced antibodies specific 
for neither whole HA antigen nor the peptide immunogens was 
observed by ELISA (data not shown), efficacy was apparently 
cell-mediated only. Thus, we conclude that this minimal-epitope 
based H1N1 influenza epitope-based vaccine is immunogenic 
and partially efficacious.
Discussion
Leading up to the present study, we used EpiMatrix, a T-cell epi-
tope prediction and sequence comparison tool, to discover cross-
conserved putative T-cell epitope sequences among the three 
hemagglutinin (HA) and neuraminidase (NA) proteins con-
tained in 2008–2009 TIV and their counterparts in pandemic 
2009 H1N1 influenza virus (A/California/04/2009).9 We found 
greater than 50% conservation of helper T and CTL epitopes 
between A/California/04/2009 and TIV HA for “supertype” 
HLA alleles, whereas conservation was lower among NA epit-
opes. A total of 16 promiscuous helper T-cell epitopes are con-
tained in the A/California/04/2009 HA sequence, of which nine 
(56%) were 100% conserved in the 2008–2009 influenza vaccine 
DR3 transgenic mice. The HLA trans-
genic mouse model represents an 
improvement over wild-type mice (and 
other animal models), because animal 
and human MHC present different T-cell 
epitopes.12 MHC class II-mediated cel-
lular immunity in the mouse MHC II 
knockout, HLA DR3 knock-in strain is 
completely restricted by human HLA and 
not by mouse MHC.13 Mice were injected 
intramuscularly with the DNA vaccine 
delivered by electroporation, three times, 
over two-week intervals. Two weeks later, 
they were boosted twice subcutaneously 
with corresponding epitope peptides for-
mulated in incomplete Freund’s adjuvant 
(IFA), with immunostimulatory CpG 
ODN 1826, CL097 and muramyl dipep-
tide adjuvants, over a two-week interval. 
A control group of mice received empty 
vector in the DNA-prime phase and pep-
tide-free IFA emulsion in the boost phase.
Three weeks following the final immu-
nization, splenocytes were isolated to 
measure T-cell responses to individual 
epitopes from individual mice by IFNγ 
ELISpot assay (n = 6/group). ELISpot 
responses were considered positive accord-
ing to the same criteria used in human 
studies described above. Immunization of 
DR3 transgenic mice stimulated statisti-
cally significant (Student t-test, P < 0.01) T-cell responses to the 
pool of epitopes and to two out of 10 individual epitopes (20%): 
HA_321–341 and HA_456–480 (Fig. 4). Out of the 10 epitopes 
evaluated, seven are predicted to bind HLA DR39; thus, two out 
of seven (29%) are true positive epitopes. By more relaxed criteria, 
epitopes HA_38–61 and HA_432–453 may also be considered 
positive as they stimulate responses that are >20 SFC per mil-
lion splenocytes, > 2 × background and statistically distinct from 
background. Both these sequences are predicted to bind HLA 
DR3, thus raising the number of immunogenic epitopes to 40% 
of those tested and 57% positively predicted sequences. Three of 
the ten epitopes (HA_319–345, HA_396–417, HA_548–563) 
are not predicted to bind HLA DR3 and were not immuno-
genic in this study. In sum, seven out of 10 (70%) of immune 
responses measured are in concordance with the immunoinfor-
matic predictions.
Next, we set out to evaluate vaccine efficacy against A/
California/07/2009 challenge in DR3 transgenic mice. Three 
weeks following the final immunization, 16 mice in each group 
were challenged intranasally with 106 PFU of virus. Mice in both 
groups became ill and lost >20% of their pre-challenge weight by 
day 7 post-infection and were sacrificed. While it was not surpris-
ing that there was no difference in morbidity between immunized 
and naïve mice, as only two to four epitopes were immunogenic, 
we did detect differences in lung viral titers. Viral burden as 
Figure 4. cell-mediated response to immunization of HLa DR3 transgenic mice with cross-
conserved H1N1 influenza class II HLa epitopes. Mice were primed with plasmid DNa vaccine 
and boosted with peptides comprising cross-conserved H1N1 influenza class II HLa epitopes or 
vaccine vehicle containing no epitopes. epitope-specific cellular responses in splenocyte cultures 
for individual and pooled epitopes were measured by IFNγ eLIspot assay. Data are the mean spot 
forming cells (sFc) per million splenocytes ± standard deviation derived for 6 mice treated com-
parably. Individual epitope and pooled epitope responses in vaccinated mice showing statistical 
significance (student’s t-test) when compared with controls are indicated: *p < 0.05. a solid line 
denotes the 50 sFc over background per million splenocytes cutoff.
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vaccine, greater protection against viral challenge may have been 
observed using this vaccine strategy, as internal antigens are well 
known to be cross-reactive in humans and animal models.15,16
This study is consistent with others showing that, in the 
absence of antibody responses, cellular immune response can 
provide effective protective immunity in animal models.17-19 With 
respect to pH1N1 infection, two independent studies demon-
strated CTLs and CD4+ T cells raised against the seasonal H1N1 
viruses, A/Brisbane/59/2007 and A/New Caledonia/20/99, 
respectively, were capable of responding against whole protein 
antigens from the pH1N1 virus.20,21 In addition, cross-reac-
tive human T helper cell responses were observed for defined 
HLA-DR4 epitopes.22 Moreover, ferrets immunized with pre-
pandemic seasonal TIV were protected from influenza disease, 
though they lacked sterilizing immunity against pH1N1 infec-
tion.23 These studies suggest that when antibodies may be unable 
to protect against variant virus challenge, T cells responding to 
conserved epitopes may act to mitigate disease severity. Putting 
the existing data on murine challenge and the current validation 
of cross-conserved epitopes into the human context, we would 
expect that priming with similar cross-conserved or “universal” 
influenza vaccine epitopes might improve the immune response 
to conventional influenza vaccines to provide enhanced protec-
tion against subsequent challenge. A number of “universal influ-
enza vaccines” based on the idea that cross-conserved B-cell 
epitopes are currently in development24-26; here we show that 
cross-conserved T-cell epitopes should also be given serious con-
sideration in vaccine design.
This study confirmed the immunogenicity of cross-reac-
tive T-cell epitopes; a similar study performed with pandemic 
H1N1-naïve individuals also confirmed the antigenicity of the 
epitopes.27 We do not presuppose that the T-cell epitopes will be 
sufficient; instead, it will be important to the field to determine 
if expanding T-cell response to cross-reactive epitopes results in 
a degree of cross-protection. The finding that T-cell responses 
to an extremely limited number (two to four) of cross-reactive 
epitopes may have the capacity to attenuate the course of novel 
H1N1-induced disease, in the absence of cross-reactive antibody 
response, may also lead to development of alternative approaches 
to “priming” immune responses and to improved means of limit-
ing future flu pandemics, through the use of vaccines that dimin-
ish the number of individuals who develop clinical symptoms 
following infection.
Methods
Peptide synthesis. Peptides were synthesized using 9-fluo-
ronylmethoxy-carbonyl (Fmoc) chemistry at 21st Century 
Biochemicals. Peptide purity was >80% as ascertained by ana-
lytical reversed phase HPLC. Peptide mass was confirmed by 
tandem mass spectrometry.
HLA binding. Peptides were assayed for HLA affinity in a 
competition binding assay based on Steere et al.28 In 96-well 
plates, a test peptide and a reference peptide compete for bind-
ing to a purified class II HLA molecule (Benaroya Research 
Institute) for 24 h at 37 °C. Non-biotinylated test peptides were 
strain H1N1 HA; 81% were either identical or had one conserva-
tive amino acid substitution. Similarly, 50% of predicted CTL 
epitopes found in A/California/04/2009 HA also were found 
in TIV HA sequences.3 Here, we confirmed immunoinformatic 
predictions in experiments designed to evaluate the capacity of 
the nine highest conserved helper T cell HA epitopes and the 
most conserved NA epitope to bind HLA and stimulate immune 
recall and de novo T-cell responses.
Recognition of the cross-conserved epitopes by HLA and 
their immunoreactivity in exposed and in vaccinated subjects 
demonstrated in this study does not imply that they are neces-
sarily protective sequences. Rather, it confirms the existence of 
cross-conserved T cells and suggests that further evaluation of 
the contributions of these cross-conserved epitopes to protection 
against infection, morbidity and mortality in the next pandemic, 
should one occur, would be entirely worthwhile. This is fur-
ther supported by the vaccination and challenge study reported 
here. Despite the fact that immunized mice had a very restricted 
immune response (2 to 4 of 7 potential epitopes were immuno-
genic), reduced viral titers were observed. Our selection of HA 
and NA epitopes only for this study was based on our interest 
in determining whether cross-conserved T-cell responses to the 
proteins usually contained in seasonal influenza vaccine would 
protect against challenge. However, it is well known that con-
ventional egg-based vaccine production results in a product that 
contains other influenza proteins. Immune response to residual 
internal proteins, which are highly cross-conserved between 
influenza strains, has been described.14 HLA restriction of this 
animal model limited the number of epitopes that were poten-
tially immunogenic as only two to four of seven induced T-cell 
response following vaccination. Had additional epitopes from 
internal proteins been included in this minimal epitope-based 
Figure 5. epitope-driven vaccine reduces lung viral titers in pandemic 
H1N1 influenza infection of HLa DR3 transgenic mice. Mice that were 
primed with plasmid DNa vaccine and boosted with peptides compris-
ing cross-conserved H1N1 influenza class II HLa epitopes or vaccine 
vehicle containing no epitopes were infected with 106 PFU a/califor-
nia/07/2009. Data are the viral burden of four mice from each group at 
two and four days post-infection as determined by viral plaque assay. 
Individual titers are denoted by filled dots and average titers by hori-
zontal lines. Titers in vaccinated mice showing statistical significance 
(student t-test) when compared with controls are indicated: **p < 0.01.
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ml IL-2 by half media replacement. Finally, 2 days later, PBMCs 
were collected and washed in preparation for antigen re-stimula-
tion to measure cytokine secretion by enzyme-linked immunospot 
(ELISpot) assay. Due to low cell recovery from two subjects, 
ELISpot assays were only performed on 16 of the 18 PBMC sam-
ples. Donor HLA class II types were determined using the One 
Lambda Micro SSPTM High Resolution HLA class II kit at the 
Hartford Hospital Transplant Immunology Laboratory. Human 
subject studies were performed in accordance with NIH regula-
tions and with the approval of the Ethical and Independent Review 
Services institutional review board.
ELISpot assay. The frequency of epitope-specific PBMCs was 
determined by IFNγ ELISpot assay using the Mabtech IFNγ 
ELISpot Kit according to the manufacturer’s protocol. Washed 
PBMCs were added at 2.5 × 105 cells per well to 96-well plates pre-
coated with anti-IFNγ antibody. Individual peptides were added 
at 10 μg/ml in triplicate wells. The pool of HA and NA pep-
tides was added at 10 μg/ml, or 1 μg/ml per peptide. Triplicate 
wells were plated with PHA (2 μg/ml) as a positive control, and 
6 wells with no peptide were used for background determina-
tion. Raw spot counts were recorded by ZellNet Consulting, Inc. 
using a Zeiss high-resolution automated ELISpot reader system 
and companion KS ELISpot software. Results were calculated 
as the average number of spots in the peptide wells, adjusted to 
spots per one million cells. A response was considered peptide-
specific if the number of spots was at least twice background, 
greater than 50 spot forming cells per well (1 response per 20 000 
PBMCs), and statistically different (P < 0.05) from that of the 
control wells by the Student t-test. ELISpot assays using splenic 
leukocytes from immunized mice were similarly performed using 
mouse IFNγ-specific reagents.
Multi-epitope DNA vaccine engineering. Epitope sequences 
were concatenated to form a multi-epitope gene containing 10 
HLA class II epitopes. Epitopes were assembled in a random 
sequence at first and then re-ordered to avoid creation of novel 
epitopes at epitope junctions using the VaccineCAD algorithm.30 
No spacer sequences were required for insertion at epitope junc-
tions to eliminate junctional immunogenicity. A histidine tag 
was incorporated downstream of the epitope sequences followed 
by two stop codons.
Genes were synthesized by GeneArt and subcloned at pre-
determined flanking restriction sites downstream of the tissue 
plasminogen activator leader sequence in pNTC8682-eRNA41H 
(Nature Technology Corporation), a DNA vaccine vector that 
accommodates FDA recommendations for construction of plas-
mid DNA vaccines.31
Plasmid DNA vaccine production. High purity plasmid for 
immunizations was prepared by Nature Technology Corporation, 
Inc. at research grade. Each plasmid underwent quality control 
testing including spectrophotometric concentration and A
260
/
A
280
 ratio determination (1.97), restriction digest analysis to 
assure the presence of the multi-epitope genes, agarose gel elec-
trophoresis determination of residual host RNA and DNA (none 
detected), and quantitative endotoxin testing (<2.0 EU/mg).
Peptide vaccine preparation. Peptides corresponding to 
epitopes in the DNA vaccine were formulated in incomplete 
evaluated over a wide range of concentrations (0.01–200 μM) 
while biotinylated standard peptide was held at a fixed concentra-
tion (0.1 μM). Peptide-class II HLA complexes were then cap-
tured on ELISA plates using pan anti-HLA-DR antibody (L243, 
BioXCell). Plates were washed and incubated with Europium-
labeled streptavidin (Perkin-Elmer) for one hour at room tem-
perature. Europium activation buffer was added to develop the 
plates for 15–20 min at room temperature before they were read 
on a Time Resolved Fluorescence (TRF) plate reader. All assays 
were performed in triplicate. Dose dependence curves were gen-
erated by fitting data using the four-parameter logistic equation, 
and IC
50
 values were calculated in SigmaPlot 11.0 (Systat). Based 
on the IC
50
 values, peptide binding to a given HLA allele was 
classified as very high affinity (<1 μM), high affinity (1–10 μM), 
moderate affinity (10–50 μM), low affinity (50–100 μM), or 
very low affinity (>100 μM). Peptides that did not inhibit the 
binding of the biotinylated reference peptide at any concentration 
were considered non-binders. Binding assays were performed for 
six alleles: DRB1*0101, DRB1*0301, DRB1*0401, DRB1*0701, 
DRB1*1101, and DRB1*1501, providing a broad representation 
of class II HLA allele binding pockets.29
PBMC collection, culture and characterization. Acute influ-
enza-like illness (ILI) subjects. During the 2009–2010 influenza 
season, patients who presented to the emergency department 
at Rhode Island Hospital with acute influenza-like symptoms 
(defined as a fever combined with a cough) were recruited for 
enrollment. Six acute ILI study subjects between the ages of 18 
and 65 were recruited and gave their consent to participate in 
the study (Lifespan IRB protocol 4074–08). Nasal washings 
were tested using reverse transcriptase polymerase chain reac-
tion (RT PCR) for determination of influenza subtype. Blood 
samples were obtained and PBMCs were separated from whole 
blood by Ficoll density gradient centrifugation and PBMCs were 
resuspended in human R-10 media (RPMI + Glutamax-88%, 
Heat inactivated human AB serum-1%, L-Glutamine-<1%, 
Gentamycin-<1%). For all subjects, enzyme-linked immunospot 
(ELISpot) assays were performed ex vivo. Donor HLA class II 
types were determined using the One Lambda Micro SSPTM 
High Resolution HLA class II kit at the Hartford Hospital 
Transplant Immunology Laboratory. Human subject studies 
were performed in accordance with NIH regulations and with 
the approval of the Lifespan and Ethical and Independent Review 
Services institutional review boards.
2011 TIV-immunized subjects. Frozen PBMCs donated by 18 
healthy adults (ages 22–77 y), before and three weeks after 2011 
TIV immunization, were generously provided by VaxDesign. If 
applicable, the date of previous vaccination (prior to donation) was 
provided for each donor. T cell assays were performed following a 
period of culture to allow for expansion of antigen-specific T cells. 
Thawed whole PBMC populations were rested overnight and then 
stimulated with peptide antigen over nine days at 37 °C under a 
5% CO
2
 atmosphere. In a 48-well plate, 5 × 106 cells in 150 μl 
Iscove’s Modified Dulbecco’s Medium (IMDM) were stimulated 
with a pool of HA and NA peptides at 10 μg/ml on Day 1. Three 
days later, IL-2 was added to 10 ng/ml and the culture volume 
raised to 300 μl. On Day 7, cells were supplemented with 10 ng/
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anesthesia. Mice were weighed daily post-infection and moni-
tored for morbidity/mortality.
Viral plaque assay. Mouse lungs were obtained from naïve 
and vaccinated groups at two and four days post-infection (n = 
4/group/time point). Lungs were weighed and homogenized at 
100 mg/ml in DMEM and stored at −80 °C. MDCK cells at low 
(<10) or medium (<20) passage were used for all plaque assays. 
750 000 cells were added to each well in 6-well plates and rested 
overnight at 37 °C under a 5% CO
2
 atmosphere. Ten-fold serial 
dilutions of lung homogenates in DMEM were made with viral 
dilutions loaded in duplicate on MDCK monolayers. Following 
a 1 h, room temperature incubation, viral suspensions were 
aspirated from wells and 2 ml warm L-15/Trypsin/agarose was 
poured onto cell monolayers. Following a 72 h incubation at 37 
°C, agarose was carefully removed and plaques were stained with 
1% Crystal Violet. Plaques were counted and PFU/ml calculated 
based on average of plaque assay duplicates.
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Freund’s adjuvant (IFA) with 10 μg each of immunostimula-
tory CpG oligodeoxynucleotide 1826 (5'-TCCATGACGT 
TCCTGACGTT-3'), muramyl dipeptide (MDP) and CL097 
(InvivoGen).
Mice. HLA DR3 transgenic mice were obtained from Dr. 
Chella David (Mayo Medical School) under commercial license. 
The mice express the HLA DR3α and β genes on a B.10-Ab0 
mouse class II-negative background.13 Experiments were con-
ducted with mice 6 to 10 weeks old at the point of initiation. 
All studies were performed in full compliance with the standards 
of the TGA Sciences, Inc. Institutional Animal Care and Use 
Committee and in accordance with NIH publications entitled 
“Principles for Use of Animals” and “Guide for the Care and Use 
of Laboratory Animals.”
Vaccinations. Vaccine and placebo-treated mice (n = 22/
group) were all female and 6–8 weeks old at the start of immu-
nizations. DNA-prime vaccine was administered to mice intra-
muscularly by electroporation using the Ichor Medical Systems 
with 20 μL of 10 μg naked DNA in sterile PBS injected into 
the quadriceps muscle. For peptide-boost immunizations, each 
mouse was anesthetized with ketamine/xylazine and adminis-
tered 100 μl IFA emulsion (50 μg peptide) subcutaneously by 
needle stick injection.
Virus preparation. Stocks of influenza A/California/07/2009 
virus were propagated in the allantoic cavity of 9- to 11-d-old 
embryonated specific pathogen-free (SPF) hen’s eggs at 37 °C. 
The allantoic fluids from eggs inoculated with each virus was 
harvested 24 h post-inoculation and tested for hemagglutinating 
activity. Eggs inoculated with viruses were incubated at 33 °C 
and were harvested 3 d post-inoculation. Infectious allantoic flu-
ids were pooled, divided into aliquots, and stored at −80 °C until 
used for studies. The viral titer was determined by serial titration 
in Madin-Darby canine kidney (MDCK) cells and calculated by 
the method developed by Reed and Muench.32 Virus preparation 
was conducted using enhanced BSL-2 containment procedures 
in laboratories approved for use by the USDA and Centers for 
Disease Control and Prevention.
Respiratory challenge. Mice were dosed with 1 × 106 PFU 
A/California/07/2009 intranasally under ketamine/xylazine 
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